The Current Opinion journals were developed out of the recognition that it is increasingly difficult for specialists to keep up to date with the expanding volume of information published in their subject. Elsevier’s Current Opinion journals comprise of 26 leading titles in life sciences and adjacent fields.

Current Opinion in Pharmacology

5-Year Impact Factor: 4.840
Issues per year: 6 issues
Editorial Board

Current Opinion in Pharmacology

The Current Opinion journals were developed out of the recognition that it is increasingly difficult for specialists to keep up to date with the expanding volume of information published in their subject. In Current Opinion in Pharmacology, we help the reader by providing in a systematic manner:
1. The views of experts on current advances in pharmacology in a clear and readable form.
2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications

Division of the subject into sections
The subject of pharmacology is divided into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance.

NeurosciencesCardiovascular and renalRespiratoryMusculoskeletalCancerImmunomodulationAnti-infectives • New technologiesGastrointestinalEndocrine and metabolic diseases

Selection of topics to be reviewed
Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.

Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.

Editorial Overview
Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.

Ethics in Publishing: General Statement

The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

For more information, please refer to:

Best Cited over the last year.

Subscribe to RSS Sciverse Scopus

Monoclonal antibody therapeutics: History and future

Over the last three decades, monoclonal antibodies have made a dramatic transformation from scientific tools to powerful human therapeutics. At present, approximately 30 therapeutic monoclonal antibodies are marketed in the United States and Europe in a variety of indications, with sales in the US alone reaching approximately $18.5 billion in 2010. This review describes how antibody engineering has revolutionized drug discovery and what are considered the key areas for future development in the…

Volume 12, Issue 5, 01 October 2012, Pp 615-622
Nicholas A P S Buss | Simon J. Henderson | Mary McFarlane | Jacintha M. Shenton | Lolke De Haan

Chemokines and cytokines in neuroinflammation leading to neuropathic pain

There has been recent evidence showing the correlation between neuroinflammation owing to the chemokine-cytokine network and neuropathic pain. Chemokines and cytokines are derived from several types of cells in the peripheral and central nervous systems following nerve injury, and are largely involved in the pathogenesis of neuropathic pain. The roles of typical inflammatory cytokines such as interleukin-1β have become the recent center of attention. There is growing evidence that inflammatory…

Volume 12, Issue 1, 01 February 2012, Pp 55-61
Norikazu Kiguchi | Yuka Kobayashi | Shiroh Kishioka

Resolution phase lipid mediators of inflammation: Agonists of resolution

Lipid mediators are appreciated for their roles in leukocyte traffic required in host defense. With identification of novel resolution phase mediators, resolvins, protectins and maresins, these three families and their aspirin-triggered forms, given their potent stereoselective actions with human cells and animal disease models, are coined specialized pro-resolving mediators (SPM). Stereochemistries of key SPM are established and several groups reported organic synthesis. Given increased…

Volume 13, Issue 4, 07 June 2013, Pp 632-640
Charles N. Serhan | Nan Chiang

Ocular perfusion pressure and ocular blood flow in glaucoma

Glaucoma is a progressive optic neuropathy of unknown origin. It has been hypothesized that a vascular component is involved in glaucoma pathophysiology. This hypothesis has gained support from studies showing that reduced ocular perfusion pressure is a risk factor for the disease. The exact nature of the involvement is, however, still a matter of debate. Based on recent evidence we propose a model including primary and secondary insults in glaucoma. The primary insult appears to happen at the…

Volume 13, Issue 1, 01 February 2013, Pp 36-42
A. Popa Cherecheanu | G. Garhofer | D. Schmidl | R. Werkmeister | L. Schmetterer

PD-1/PD-L1 inhibitors

© 2015 Elsevier Ltd. All rights reserved. Tumors may adopt normal physiologic checkpoints for immunomodulation leading to an imbalance between tumor growth and host surveillance. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction. Nivolumab and pembrolizumab are the anti-PD-1 antibodies that are currently the furthest in clinical development, and anti-PD-L1 agents under investigation include…

Volume 23, Issue , 03 June 2015, Pp 32-38
Joel Sunshine | Janis M. Taube

Selective PDE inhibitors as novel treatments for respiratory diseases

Phosphodiesterases (PDEs) are a family of enzymes which catalyse the metabolism of the intracellular cyclic nucleotides, c-AMP and c-GMP that are expressed in a variety of cell types and in the context of respiratory diseases, It is now recognised that the use of PDE3, PDE4 and mixed PDE3/4 inhibitors can provide clinical benefit to patients with asthma or chronic obstructive pulmonary disease (COPD). The orally active PDE4 inhibitor Roflumilast-n-oxide has been approved for treatment of severe…

Volume 12, Issue 3, 01 June 2012, Pp 275-286
Clive P. Page | Domenico Spina

Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease

Nitric oxide (NO) produced by the endothelial NO synthase (eNOS) is an antihypertensive, antithrombotic and anti-atherosclerotic molecule. Hypercholesterolemia leads to a reduction in vascular NO bioavailability. This is attributed to a dysfunction of the eNOS enzyme and a reduced eNOS activity. NADPH oxidase-mediated oxidative stress leads to oxidation of tetrahydrobiopterin (BH 4 ), the essential cofactor of eNOS. In BH 4 deficiency, oxygen reduction uncouples from NO synthesis, thereby…

Volume 13, Issue 2, 01 April 2013, Pp 161-167
Huige Li | Ulrich Förstermann

Oxidative stress and mitochondrial dysfunction in glaucoma

Mitochondrial dysfunction increases reactive oxygen species (ROS) production and when this overwhelms the cellular antioxidant defences, oxidative stress ensues. Oxidative stress is recognized as a common pathologic pathway in many neurodegenerative diseases. Recent reports have also demonstrated oxidative stress in ocular tissues derived from experimental glaucoma models and clinical samples. There is also accumulating evidence pointing to mitochondrial dysfunction being present in some…

Volume 13, Issue 1, 01 February 2013, Pp 12-15
Vicki Chrysostomou | Fatemeh Rezania | Ian A. Trounce | Jonathan G. Crowston

Update on the antibiotic resistance crisis

© 2014 Elsevier Ltd. All right reserved. Antibiotics tend to lose their efficacy over time due to the emergence and dissemination of resistance among bacterial pathogens. Strains with resistance to multiple antibiotic classes have emerged among major Gram-positive and Gram-negative species including Staphylococcus aureus, Enterococcus spp., Pseudomonas aeruginosa, Acinetobacter spp. Enterobacteriaceae, and Neisseria gonorrhoeae. With some Gram-negatives, resistance may involve most or even all…

Volume 18, Issue , 01 January 2014, Pp 56-60
Gian Maria Rossolini | Fabio Arena | Patrizia Pecile | Simona Pollini

Recent advances in osteosarcoma

Although osteosarcoma (OS) is a rare malignancy, it is ranked among the leading causes of cancer-related death in the pediatric age group. The cancer's low prevalence and its large tumor heterogeneity make it difficult to obtain meaningful progress in patient survival. In this review we present an overview of current clinical trials which largely focus on stimulation of the immune system or rely on the inhibition of kinases such as Src and mTOR. The potential efficacy of tumor-targeted TNFalpha…

Volume 16, Issue 1, 01 January 2014, Pp 15-23
Sander M. Botter | Dario Neri | Bruno Fuchs

New developments in Toll-like receptor targeted therapeutics

Toll-like receptors (TLRs) play a crucial role in host defence and inflammation. Given that a significant amount of evidence implicates TLRs in the pathogenesis of immune diseases and cancer, and their activation occurs early in the inflammatory cascade, they are attractive targets for novel therapeutic agents. Potential therapeutics include TLR-targeted antibodies, small molecules and nucleic acid based drugs. Agonists are being tested in vaccines against hepatitis C and influenza as well as…

Volume 12, Issue 4, 01 August 2012, Pp 510-518
Dympna J. Connolly | Luke Aj O'Neill

Cholesterol and prostate cancer

Prostate cancer risk can be modified by environmental factors, however the molecular mechanisms affecting susceptibility to this disease are not well understood. As a result of a series of recently published studies, the steroidal lipid, cholesterol, has emerged as a clinically relevant therapeutic target in prostate cancer. This review summarizes the findings from human studies as well as animal and cell biology models, which suggest that high circulating cholesterol increases risk of…

Volume 12, Issue 6, 01 December 2012, Pp 751-759
Kristine Pelton | Michael R. Freeman | Keith R. Solomon

Gut microbiota, enteroendocrine functions and metabolism

The gut microbiota affects host metabolism through a number of physiological processes. Emerging evidence suggests that gut microbes interact with the host through several pathways involving enteroendocrine cells (e.g. L cells). The activation of specific G protein coupled receptors expressed on L cells (e.g. GPR41, GPR43, GPR119 and TGR5) triggers the secretion of glucagon-like peptides (GLP-1 and GLP-2) and PYY. These gut peptides are known to control energy homeostasis, glucose metabolism,…

Volume 13, Issue 6, 25 September 2013, Pp 935-940
Patrice D. Cani | Amandine Everard | Thibaut Duparc

Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease

Cytokines are critical for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease. A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacological targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases. These receptors rely on Janus family of kinases (Jaks) for signal transduction. Recently the first Jak inhibitor…

Volume 12, Issue 4, 01 August 2012, Pp 464-470
Apostolos Kontzias | Alexander Kotlyar | Arian Laurence | Paul Changelian | John J. O'Shea

Schizophrenia: From dopaminergic to glutamatergic interventions

Schizophrenia might be considered a neurodevelopmental disease. However, the fundamental process(es) associated with this disease remain(s) uncertain. Many lines of evidence suggest that schizophrenia is associated with excessive stimulation of dopamine D2 receptors in the associative striatum, with a lack of stimulation of dopamine D1 receptors in prefrontal cortex, and with modifications in prefrontal neuronal connectivity involving glutamate transmission at N-methyl aspartate (NMDA)…

Volume 14, Issue 1, 01 February 2014, Pp 97-102
Marc Laruelle

Protein-protein interactions as druggable targets: Recent technological advances

Classical target-based drug discovery, where large chemical libraries are screened using inhibitory assays for a single target, has struggled to find ligands that inhibit protein-protein interactions (PPI). Nevertheless, in the past decade there have been successes that have demonstrated that PPI can be useful drug targets, and the field is now evolving fast. This review focuses on the new approaches and concepts that are being developed to tackle these challenging targets: the use of fragment…

Volume 13, Issue 5, 01 October 2013, Pp 791-796
Alicia P. Higueruelo | Harry Jubb | Tom L. Blundell

Tumour-associated macrophages and cancer

Our understanding of the complex roles and functions of tumour-associated myeloid cells has improved vastly over the last few years. Alternatively activated macrophages, TAMs, are an abundant part of solid and haematological malignancies and have been linked with progression, metastasis and resistance to therapy. Still, characterisation and TAM targeting is hindered by a lack of TAM specific markers, but advances in next generation technologies are rapidly increasing our understanding of the…

Volume 13, Issue 4, 17 June 2013, Pp 595-601
Jenny Cook | Thorsten Hagemann

Improving known classes of antibiotics: An optimistic approach for the future

New antibiotic agents are desperately needed to treat the multidrug-resistant pathogens that continue to emerge at alarming rates. Many of the agents that have entered full clinical development since 1995 have been members of previously accepted classes of antibiotics. Among these are a new aminoglycoside (plazomicin), anti-MRSA cephalosporins (ceftobiprole and ceftaroline), a monocyclic β-lactam (BAL30072), the β-lactamase inhibitor combination of tazobactam with the anti-pseudomonal…

Volume 12, Issue 5, 01 October 2012, Pp 527-534
Karen Bush

Hyperalgesia by synaptic long-term potentiation (LTP): An update

Long-term potentiation of synaptic strength (LTP) in nociceptive pathways shares principle features with hyperalgesia including induction protocols, pharmacological profile, neuronal and glial cell types involved and means for prevention. LTP at synapses of nociceptive nerve fibres constitutes a contemporary cellular model for pain amplification following trauma, inflammation, nerve injury or withdrawal from opioids. It provides a novel target for pain therapy. This review summarizes recent…

Volume 12, Issue 1, 01 February 2012, Pp 18-27
Jürgen Sandkühler | Doris Gruber-Schoffnegger

Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: Design considerations and clinical applications

Superparamagnetic iron oxide nanoparticles (SPION) based magnetic resonance imaging (MRI) is a powerful non-invasive tool in biomedical imaging, clinical diagnosis and therapy. In this review, the physicochemical properties of SPION and their in vivo performance were thoroughly discussed, also covering how surface engineering will prolong the circulation time and overcome biological barriers at organ, tissue, and cellular levels. Clinical applications and future potentials of SPION based MR…

Volume 18, Issue , 01 January 2014, Pp 18-27
Rongrong Jin | Bingbing Lin | Danyang Li | Hua Ai

Antioxidant pharmacological therapies for COPD

Increased oxidative stress occurs in the lungs and systemically in COPD, which plays a role in many of the pathogenic mechanisms in COPD. Hence, targeting local lung and systemic oxidative stress with agents that modulate the antioxidants/redox system or boost endogenous antioxidants would be a useful therapeutic approach in COPD. Thiol antioxidants (N-acetyl-l-cysteine [NAC] and N-acystelyn, carbocysteine, erdosteine, and fudosteine) have been used to increase lung thiol content. Modulation of…

Volume 12, Issue 3, 01 June 2012, Pp 256-265
Irfan Rahman | William MacNee

Communication between gastrointestinal bacteria and the nervous system

In the past few years, intestinal microbiota has emerged as a novel target for the treatment of gut-brain axis alterations. These include functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), which can be comorbid with stress-related psychiatric conditions. Thus, modulation of the microbiota (e.g. with the use of probiotics) could be proposed as a novel strategy not only for the treatment of IBS but also as an adjuvant for psychiatric treatment of anxiety and…

Volume 12, Issue 6, 01 December 2012, Pp 667-672
Javier A. Bravo | Marcela Julio-Pieper | Paul Forsythe | Wolfgang Kunze | Timothy G. Dinan | John Bienenstock | John F. Cryan

IL-36 in psoriasis

Psoriasis is a common but severe skin disease with significant health consequences, both physical and psychological. Evidence has emerged during the past several years pointing to a key role for IL-36 in psoriasis. Overexpression of IL-36 in mouse skin leads to a disease quite similar to human plaque psoriasis, and inhibition of IL-36 in human psoriatic skin ameliorates the inflammation. Loss of the natural antagonist of IL-36, IL-36Ra, results in a different, more severe skin disease known as…

Volume 12, Issue 4, 01 August 2012, Pp 486-490
Je Towne | Je Sims

Metabotropic glutamate receptors and the control of chronic pain

Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective…

Volume 12, Issue 1, 01 February 2012, Pp 28-34
Santina Chiechio | Ferdinando Nicoletti

New insights in the pathogenesis and treatment of normal tension glaucoma

Increased intraocular pressure (IOP) is a major risk factor for glaucomatous damage and reducing IOP improves prognosis. Nevertheless, there is little doubt that other risk factors besides IOP such as unstable ocular perfusion are involved. Blood flow is unstable if either the IOP fluctuates at a high level (or blood pressure fluctuates at a low level) or if the autoregulation of blood flow disturbed. A common cause for a disturbed OBF autoregulation is a primary vascular dysregulation (PVD)…

Volume 13, Issue 1, 01 February 2013, Pp 43-49
Maneli Mozaffarieh | Josef Flammer